Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc.
04:17am, Monday, 10'th Aug 2026
Contravisory Investment Management Inc. increased its position in shares of Moderna, Inc. (NASDAQ: MRNA) by 1,387.6% during the undefined quarter, according to its most recent disclosure with the Secu
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
11:46am, Friday, 07'th Aug 2026
MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
01:15am, Friday, 07'th Aug 2026
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
This new kind of flu shot by Moderna has just been approved by the FDA
04:21pm, Thursday, 06'th Aug 2026
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufactur
Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal
02:35pm, Thursday, 06'th Aug 2026
Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Fo
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine
11:06am, Thursday, 06'th Aug 2026
The U.S. Food and Drug Administration (FDA) on Wednesday approved Moderna Inc.'s (NASDAQ:MRNA) mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
Moderna Stock Climbs on Flu Vaccine Approval
09:08am, Thursday, 06'th Aug 2026
Moderna Inc (NASDAQ:MRNA) is up 3.6% at $58.30 ahead of the open, after the U.S. Food and Drug Administration (FDA) approved the company's mRNA-based seasonal flu vaccine , mFluvis, for adults ages 50
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future
08:26am, Thursday, 06'th Aug 2026
Moderna's mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
Sandisk, AppLovin, Moderna, and More Stocks That Explain Today's Market
06:42am, Thursday, 06'th Aug 2026
Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market's sky-high expectations.
FDA Approves First mRNA Flu Vaccine For Older Adults
03:10am, Thursday, 06'th Aug 2026
"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Mode
The decision caps a seven-month review that included a rare refusal to consider the shot at all.
US FDA approves first mRNA flu shot from Moderna
10:20pm, Wednesday, 05'th Aug 2026
The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
10:15pm, Wednesday, 05'th Aug 2026
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswir
Cetera Investment Advisers Has $4.13 Million Stake in Moderna, Inc. $MRNA
03:43am, Wednesday, 05'th Aug 2026
Cetera Investment Advisers boosted its position in shares of Moderna, Inc. (NASDAQ: MRNA) by 28.1% during the undefined quarter, according to the company in its most recent filing with the SEC. The in
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
12:35pm, Tuesday, 04'th Aug 2026
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
